PATIENTS

Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment

ACOBIOM

Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy

CLINICS & HOSPITALS

Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences

GemciTest ®

The first diagnostic to predict the patient response in pancreatic cancer treatment

PANCREATIC CANCER

A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.

DIAGNOSTIC

A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response

GEMCITABINE

The less toxic and expensive chemotherapy in pancreatic cancer treatment

BLOOD RNA-SIGNATURE

A combination of biomarkers to identify patients most likely to benefit from gemcitabine

To improve the patient’s quality of life during pancreatic cancer treatment

Our Expertises

Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.

BIOMARKERS

Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.

BIOINFORMATICS

Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic and Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.

PRECISION MEDICINE

Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.

GENOMICS

A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.

Latest News

GemciTest - In vitro diagnostic medical device for the prediction of patient response in the treatment of the pancreas with gemcitabine

Publication in the Cancers journal on the benefits of GemciTest®

A scientific publication in Cancers, a peer reviewed scientific journal, presents the capabilities of Acobiom’s GemciTest® to identify the pancreatic cancer patients who are most likely to benefit from gemcitabine-based treatment as the first approach.

Read more
Pink Ribbon - The Jerome Lejeune Institute and ACOBIOM identified recently new prognostic factors in breast cancer

The Jerome Lejeune Institute and ACOBIOM identified recently new prognostic factors in breast cancer

In a recent study, ACOBIOM, in partnering with the Jerome Lejeune Institute, characterized molecular mechanisms that could help to better understand the decreased incidence of Breast Cancer in women with Down Syndrome (Trisomy 21).

Read more

AG2R LA MONDIALE supports the GemciTest®

AG2R LA MONDIALE supports the improvement of medical management of pancreatic cancer with GemciTest®

Read more
ABOUT ACOBIOM

Since its foundation, Acobiom has always been at the forefront of Medical Innovation.

Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.

FOR MORE INFORMATION
Big Data - Acobiom

Contact us